# Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

> **NCT01811472** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** LCQ908
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01811472
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01811472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01811472, "Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01811472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*